Cargando…

Genomic loss of the putative tumor suppressor gene E2A in human lymphoma

The transcription factor E2A is essential for lymphocyte development. In this study, we describe a recurrent E2A gene deletion in at least 70% of patients with Sézary syndrome (SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell cycle progression via derepressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Steininger, Anne, Möbs, Markus, Ullmann, Reinhard, Köchert, Karl, Kreher, Stephan, Lamprecht, Björn, Anagnostopoulos, Ioannis, Hummel, Michael, Richter, Julia, Beyer, Marc, Janz, Martin, Klemke, Claus-Detlev, Stein, Harald, Dörken, Bernd, Sterry, Wolfram, Schrock, Evelin, Mathas, Stephan, Assaf, Chalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149217/
https://www.ncbi.nlm.nih.gov/pubmed/21788410
http://dx.doi.org/10.1084/jem.20101785
_version_ 1782209432567939072
author Steininger, Anne
Möbs, Markus
Ullmann, Reinhard
Köchert, Karl
Kreher, Stephan
Lamprecht, Björn
Anagnostopoulos, Ioannis
Hummel, Michael
Richter, Julia
Beyer, Marc
Janz, Martin
Klemke, Claus-Detlev
Stein, Harald
Dörken, Bernd
Sterry, Wolfram
Schrock, Evelin
Mathas, Stephan
Assaf, Chalid
author_facet Steininger, Anne
Möbs, Markus
Ullmann, Reinhard
Köchert, Karl
Kreher, Stephan
Lamprecht, Björn
Anagnostopoulos, Ioannis
Hummel, Michael
Richter, Julia
Beyer, Marc
Janz, Martin
Klemke, Claus-Detlev
Stein, Harald
Dörken, Bernd
Sterry, Wolfram
Schrock, Evelin
Mathas, Stephan
Assaf, Chalid
author_sort Steininger, Anne
collection PubMed
description The transcription factor E2A is essential for lymphocyte development. In this study, we describe a recurrent E2A gene deletion in at least 70% of patients with Sézary syndrome (SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell cycle progression via derepression of the protooncogene MYC and the cell cycle regulator CDK6. Furthermore, by examining the gene expression profile of SS cells after restoration of E2A expression, we identify several E2A-regulated genes that interfere with oncogenic signaling pathways, including the Ras pathway. Several of these genes are down-regulated or lost in primary SS tumor cells. These data demonstrate a tumor suppressor function of E2A in human lymphoid cells and could help to develop new treatment strategies for human lymphomas with altered E2A activity.
format Online
Article
Text
id pubmed-3149217
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-31492172012-02-01 Genomic loss of the putative tumor suppressor gene E2A in human lymphoma Steininger, Anne Möbs, Markus Ullmann, Reinhard Köchert, Karl Kreher, Stephan Lamprecht, Björn Anagnostopoulos, Ioannis Hummel, Michael Richter, Julia Beyer, Marc Janz, Martin Klemke, Claus-Detlev Stein, Harald Dörken, Bernd Sterry, Wolfram Schrock, Evelin Mathas, Stephan Assaf, Chalid J Exp Med Brief Definitive Report The transcription factor E2A is essential for lymphocyte development. In this study, we describe a recurrent E2A gene deletion in at least 70% of patients with Sézary syndrome (SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell cycle progression via derepression of the protooncogene MYC and the cell cycle regulator CDK6. Furthermore, by examining the gene expression profile of SS cells after restoration of E2A expression, we identify several E2A-regulated genes that interfere with oncogenic signaling pathways, including the Ras pathway. Several of these genes are down-regulated or lost in primary SS tumor cells. These data demonstrate a tumor suppressor function of E2A in human lymphoid cells and could help to develop new treatment strategies for human lymphomas with altered E2A activity. The Rockefeller University Press 2011-08-01 /pmc/articles/PMC3149217/ /pubmed/21788410 http://dx.doi.org/10.1084/jem.20101785 Text en © 2011 Steininger et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Brief Definitive Report
Steininger, Anne
Möbs, Markus
Ullmann, Reinhard
Köchert, Karl
Kreher, Stephan
Lamprecht, Björn
Anagnostopoulos, Ioannis
Hummel, Michael
Richter, Julia
Beyer, Marc
Janz, Martin
Klemke, Claus-Detlev
Stein, Harald
Dörken, Bernd
Sterry, Wolfram
Schrock, Evelin
Mathas, Stephan
Assaf, Chalid
Genomic loss of the putative tumor suppressor gene E2A in human lymphoma
title Genomic loss of the putative tumor suppressor gene E2A in human lymphoma
title_full Genomic loss of the putative tumor suppressor gene E2A in human lymphoma
title_fullStr Genomic loss of the putative tumor suppressor gene E2A in human lymphoma
title_full_unstemmed Genomic loss of the putative tumor suppressor gene E2A in human lymphoma
title_short Genomic loss of the putative tumor suppressor gene E2A in human lymphoma
title_sort genomic loss of the putative tumor suppressor gene e2a in human lymphoma
topic Brief Definitive Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149217/
https://www.ncbi.nlm.nih.gov/pubmed/21788410
http://dx.doi.org/10.1084/jem.20101785
work_keys_str_mv AT steiningeranne genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT mobsmarkus genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT ullmannreinhard genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT kochertkarl genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT kreherstephan genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT lamprechtbjorn genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT anagnostopoulosioannis genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT hummelmichael genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT richterjulia genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT beyermarc genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT janzmartin genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT klemkeclausdetlev genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT steinharald genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT dorkenbernd genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT sterrywolfram genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT schrockevelin genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT mathasstephan genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma
AT assafchalid genomiclossoftheputativetumorsuppressorgenee2ainhumanlymphoma